West Pharmaceutical Services Announces Transfer of SmartDose® System Rights with Future Developments

West Pharmaceutical Services Transfers SmartDose® System Rights

West Pharmaceutical Services, Inc., a recognized leader in the injectable drug administration sector, has successfully completed the transfer of manufacturing and supply rights for its SmartDose® 3.5mL On-Body Delivery System. This strategic move was finalized on July 1, 2026, as planned, marking a significant milestone in the company’s ongoing efforts to streamline operations and focus on innovation.

The SmartDose® device, which is crucial for patient-centered drug delivery, utilizes advanced technology aimed at improving medication administration. The sale underscores West's commitment to enhancing its product offerings and ensuring safe delivery methods for potentially life-saving medications.

In conjunction with this transfer, West has confirmed its dedication to continuing the development and manufacturing of other variants of the SmartDose system. Notably, the SmartDose® 10mL On-Body Delivery System will remain within West's portfolio, showcasing the company's adaptive technology designed to meet the needs of larger drug volumes.

About West Pharmaceutical Services

Headquartered in Exton, Pennsylvania, West Pharmaceutical Services, Inc. has established itself as a trusted partner for both established and emerging pharmaceutical developers. Its extensive experience ensures the secure packaging and effective delivery of critical medications. The organization boasts over 10,000 employees across 50 locations and operates 26 manufacturing facilities worldwide.

In fiscal year 2025, West recorded impressive financial results, generating $3.07 billion in net sales. The company's shares are traded under the NYSE ticker symbol WST and are included in the prestigious Standard & Poor's 500 index. This financial strength emphasizes West's position as a key player in the industry.

By delivering over 41 billion components and devices annually, West Pharmaceutical Services remains at the forefront of injectable solutions, highlighting its role in the healthcare supply chain.

Commitment to Innovation

The completion of this deal allows West Pharmaceutical Services to not only focus on larger volume delivery systems but also to innovate further in the field of injectable drug administration. The company is dedicated to delivering safe and effective solutions and is strategically positioned for future growth.

As the healthcare landscape continues to evolve rapidly, West's adaptability and commitment to research and development will ensure that it meets the demands of modern medicine. The ongoing improvements in their product lines, like the SmartDose series, will contribute to better patient outcomes and a stronger healthcare system overall.

Looking Forward

As West Pharmaceutical Services moves forward, stakeholders and consumers can anticipate continued advancements in drug delivery technology. The company’s focus on enhancing user experience and patient safety reflects its mission to provide the highest quality injectable solutions to those in need.

For more information about West Pharmaceutical Services and its extensive product offerings, visit westpharma.com.

As the world of pharmaceuticals continues to evolve, West’s actions signal a robust commitment to innovation and patient-centered care. With the SmartDose® System rights transferred, West is poised to pursue new opportunities while reinforcing its core values of safety and effectiveness in healthcare delivery.